IBAB Ion Beam Applications SA

IBA and Apollo Hospitals sign a term sheet for one Proteus®ONE system plus a second one in option to be installed in India

IBA and Apollo Hospitals sign a term sheet for one Proteus®ONE system plus a second one in option to be installed in India


Louvain-La-Neuve, Belgium, March 04, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a term sheet with Apollo Hospitals Enterprise Limited (AHEL) for the supply of one Proteus®ONE1 compact proton therapy solution plus a second one in option. Apollo will therefore expand access to proton therapy in India. The term sheet was signed in the presence of Her Royal Highness Princess Astrid of Belgium.

These systems expand upon the existing collaboration between the two partners, with AHEL having previously selected an IBA Proteus®PLUS1 system in 2013 and introduced the first proton beam therapy in India. AHEL expects to start treating patients with the Proteus®ONE systems by 2028.

Proteus®ONE is the market leading compact proton therapy system, which is upgradable over time to continue providing the latest technology to IBA users. The systems will include DynamicARC®2 beam delivery capabilities when regulatory clearance is granted.

The typical end-user price for a Proteus®ONE system with a multi-year maintenance contract ranges between EUR 35 and 45 million.

Olivier Legrain, Chief Executive Officer of IBA, commented: “These contracts expand upon the close relationship we have built for more than a decade with Apollo Hospitals. Having an existing customer reaffirm their confidence in our solutions demonstrates not only the reliability and superiority of the IBA portfolio but also highlights the level of excellence of the services we deliver. We look forward to further strengthening our relationship with Apollo as we enable more patients in India to gain access to this life-saving treatment modality.”

Dr. Prathap C Reddy, Founder and Chairman of Apollo Hospitals Enterprise Ltd, added: Our relentless pursuit of excellence in healthcare drives us to bring the most advanced medical technologies to India. In 2019, Apollo commissioned the first proton therapy system in India and till date we have treated over 2000 patients from over 147 countries. We are excited to partner with IBA again as we expand our proton therapy treatment capacity. The addition of Proteus®ONE further cements our position as a global leader in proton beam therapy treatments, enabling us to deliver superior clinical outcomes and improve the quality of life for cancer patients in India and worldwide.”

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered to be the most advanced form of radiation therapy available today, industrial sterilization, radiopharmaceuticals, and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at:

About Apollo Hospitals Entreprise Limited

Apollo Hospitals Enterprise Ltd (AHEL) revolutionised healthcare when Dr. Prathap C. Reddy opened the first hospital in Chennai in 1983. Today, AHEL is India’s largest integrated healthcare platform with over 10,000 beds across 73 hospitals, over 6000 pharmacies and over 200 clinics and diagnostic centres, as well as 150 telemedicine centres. It is the world’s leading Cardiac Centre with over 200,000 surgeries and the world’s largest private cancer care provider. Apollo continues to invest in research to bring the most cutting-edge technologies, equipment and treatment protocols to ensure patients have the best available care in the world. Apollo’s 100,000 family members are dedicated to bringing the best care making a better world.

CONTACTS

IBA

Olivier Lechien

Corporate Communication Director



ICR Healthcare

Amber Fennell, Angela Gray, Lucy Featherstone

+44 (0) 20 3709 5700





1 Proteus®ONE and Proteus®PLUS are the brand names of Proteus®235.

2 DynamicARC® is a registered brand of the IBA’s Proton Arc therapy solution currently under development phase.



Attachment



EN
04/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

 PRESS RELEASE

IBA and Apollo Hospitals sign a term sheet for one Proteus®ONE system ...

IBA and Apollo Hospitals sign a term sheet for one Proteus®ONE system plus a second one in option to be installed in India Louvain-La-Neuve, Belgium, March 04, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a term sheet with Apollo Hospitals Enterprise Limited (AHEL) for the supply of one Proteus®ONE1 compact proton therapy solution plus a second one in option. Apollo will therefore expand access to proton therapy in India. The te...

 PRESS RELEASE

IBA et Apollo Hospitals signent une lettre d’intention pour l'installa...

IBA et Apollo Hospitals signent une lettre d’intention pour l'installation d’un système Proteus®ONE et d’un second en option en Inde Louvain-la-Neuve, Belgique, le 4 mars 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et le premier fournisseur de solutions de protonthérapie pour le traitement du cancer, annonce aujourd'hui avoir signé une lettre d’intention avec Apollo Hospitals Enterprise Limited (AHEL) pour la fourniture d’une solution de protonthérapie compacte Proteus®ONE1 et d’une seconde en option. Apollo va ainsi é...

 PRESS RELEASE

IBA Notice of Full Year 2024 Results and Conference Call

IBA Notice of Full Year 2024 Results and Conference Call FY24 results meeting to take place as a hybrid event on Thursday, 20 March 2025 at 2:30pm CET Louvain-la-Neuve, Belgium, 27 February 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the full year 2024 on Thursday, 20 March 2025 at 7am CET. Conference Call Information IBA’s management team will host a hybrid event, including a conference call and webcast conducted in English, to present the full year results, foll...

 PRESS RELEASE

Publication des résultats annuels 2024 d’IBA et conférence web

Publication des résultats annuels 2024 d’IBA et conférence web La conférence sur les résultats annuels aura lieu le jeudi 20 mars 2025 à 14h30, heure de Bruxelles Louvain-la-Neuve, Belgique, le 27 février 2025 - IBA (Ion Beam Applications S.A.), le leader mondial de la technologie des accélérateurs de particules, annonce qu’elle publiera ses résultats financiers consolidés de l’exercice 2024 le jeudi 20 mars 2025 à 7h00, heure de Bruxelles. Informations relatives à la conférence La direction du groupe IBA présentera les résultats de l’exercice 2024 lors d’un événement hybride incluant u...

Guy Sips ... (+6)
  • Guy Sips
  • Kristof Samoy
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste

Morning Notes : ABI BB, ABN NA, AED BB, ASM NA, DECB BB, IBAB BB, VPK ...

: ABI BB, ABN NA, AED BB, ASM NA, DECB BB, IBAB BB, VPK NA, WKL NA, AZE BB, DEME BB, JDEP NA

ResearchPool Subscriptions

Get the most out of your insights

Get in touch